Compile Data Set for Download or QSAR
Report error Found 76 Enz. Inhib. hit(s) with all data for entry = 11471
TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618670(US11760761, Compound D-17)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618679(US11760761, Compound E-7)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618678(US11760761, Compound E-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618677(US11760761, Compound E-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618676(US11760761, Compound E-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618675(US11760761, Compound E-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618674(US11760761, Compound E-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618673(US11760761, Compound E-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618672(US11760761, Compound D-19)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618671(US11760761, Compound D-18)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618680(US11760761, Compound F-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618669(US11760761, Compound D-16)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618668(US11760761, Compound D-15)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618667(US11760761, Compound D-14)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618666(US11760761, Compound D-13)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618665(US11760761, Compound D-12)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618664(US11760761, Compound D-11)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618663(US11760761, Compound D-10)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618662(US11760761, Compound D-9)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618689(US11760761, Compound H-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618698(US11760761, Compound K-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618697(US11760761, Compound K-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618696(US11760761, Compound H-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618695(US11760761, Compound H-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618694(US11760761, Compound J-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618693(US11760761, Compound J-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618692(US11760761, Compound J-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618691(US11760761, Compound I-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618690(US11760761, Compound H-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618661(US11760761, Compound D-8)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618688(US11760761, Compound H-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618687(US11760761, Compound H-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618686(US11760761, Compound G-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618685(US11760761, Compound G-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618684(US11760761, Compound G-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618683(US11760761, Compound G-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618682(US11760761, Compound F-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618681(US11760761, Compound F-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618622(US11760761, Compound A-10)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618641(US11760761, Compound C-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618640(US11760761, Compound C-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618639(US11760761, Compound B-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618638(US11760761, Compound B-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618637(US11760761, Compound B-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618572(US11760761, Compound B-1 | US11760761, Compound A-...)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618633(US11760761, Compound A-13)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618624(US11760761, Compound A-12)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618623(US11760761, Compound A-11)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618642(US11760761, Compound C-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618615(US11760761, Compound A-9)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 76 total ) | Next | Last >>
Jump to: